Ocular Therapeutix (OCUL) Receivables - Net (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Receivables - Net of $30.3 million for Q2 2026, little changed year-over-year from $30.4 million in Q2 2025, and up 24.29% on a QoQ basis from $24.3 million in Q1 2026.
Ocular Therapeutix (OCUL) Receivables - Net (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Receivables - Net for 14 years, with the latest figure at $30.3 million in Q2 2026.
- Receivables - Net for Q2 2026 came in at $30.3 million, changed 0.5% year-over-year; the trailing twelve-month figure through Jun 2026 was $30.3 million (changed 0.5% YoY), and the FY2025 annual result was $30.6 million, down 5.37% from the prior year.
- Receivables - Net advanced to $30.3 million in Q2 2026, from $24.3 million in the prior quarter.
- Over five years, Receivables - Net peaked at $32.4 million in Q4 2024 and troughed at $19.8 million in Q3 2022.
- A 5-year average of $26.3 million and a median of $26.4 million in 2023 frame the typical range for Receivables - Net.
- The widest annual swing landed in 2022, when Receivables - Net surged 70.25%; it then declined 8.98% in 2023.
- A 5-year view of Receivables - Net shows it stood at $21.3 million in 2022, then rose by 22.76% to $26.2 million in 2023, then climbed by 23.72% to $32.4 million in 2024, then decreased by 5.37% to $30.6 million in 2025, then declined by 1.27% to $30.3 million in 2026.
- Per Business Quant data, the three most recent Receivables - Net figures were $30.3 million in Q2 2026, $24.3 million in Q1 2026, and $30.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.26 Mn |
| Jun 30, 2026 | 30.26 Mn |
| Mar 31, 2026 | 24.35 Mn |
| Mar 31, 2026 | 24.35 Mn |
| Dec 31, 2025 | 30.65 Mn |
| Dec 31, 2025 | 30.65 Mn |
| Sep 30, 2025 | 30.77 Mn |
| Sep 30, 2025 | 30.77 Mn |
| Jun 30, 2025 | 30.41 Mn |
| Jun 30, 2025 | 30.41 Mn |
| Mar 31, 2025 | 25.22 Mn |
| Mar 31, 2025 | 25.22 Mn |
| Dec 31, 2024 | 32.39 Mn |
| Dec 31, 2024 | 32.39 Mn |
| Sep 30, 2024 | 30.24 Mn |
| Sep 30, 2024 | 30.24 Mn |
| Jun 30, 2024 | 30.23 Mn |
| Jun 30, 2024 | 30.23 Mn |
| Mar 31, 2024 | 26.55 Mn |
| Mar 31, 2024 | 26.55 Mn |